Search Patents
  • Methods, Compositions, and Systems for Detecting Coronavirus Neutralizing Antibodies
    Publication number: 20220065869
    Abstract: The present disclosure relates to methods, compositions, and systems for detecting whether a subject exposed to a coronavirus has developed a neutralizing antibody response. Also disclosed are methods for determining whether a patient infected by a coronavirus is likely to respond to treatment with an antibody preparation. Also disclosed are methods for detecting the level of neutralizing antibody response in a sample of serum from a subject exposed to a coronavirus or to a coronavirus vaccine.
    Type: Application
    Filed: June 25, 2021
    Publication date: March 3, 2022
    Inventors: Christos J. Petropoulos, Mary T. Wrin, Danielle DiTirro
  • METHODS AND COMPOSITIONS FOR TREATING A CORONAVIRUS INFECTION
    Publication number: 20240116996
    Abstract: The disclosure provides methods of treating an infection by a coronavirus with a fibroblast growth factor (“FGF”). Also provided herein are FGFs for treating an infection by a coronavirus and their use in the manufacture of a medicament for treating an infection by a coronavirus.
    Type: Application
    Filed: April 5, 2022
    Publication date: April 11, 2024
    Inventor: Seth P. FINKLESTEIN
  • CANINE RESPIRATORY CORONAVIRUS (CRCV) SPIKE PROTEIN, POLYMERASE AND HEMAGGLUTININ/ESTERASE
    Publication number: 20090081780
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43.
    Type: Application
    Filed: September 26, 2008
    Publication date: March 26, 2009
    Applicant: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE
    Publication number: 20210275664
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 9, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Coronavirus Immunogenic Compositions, Methods and Uses Thereof
    Publication number: 20220226465
    Abstract: The present specification discloses broad-spectrum, pan-Coronavirus immunogenic composition including amino acid-based, broad-spectrum, pan-Coronavirus immunogenic compositions and nucleotide-based, broad-spectrum, pan-Coronavirus immunogenic compositions, methods and uses for preventing or treating a Coronavirinae-based infection or pathology as well as methods and uses of creating, maintaining or restoring antigenic memory to one or more Coronavirus species, strains, genotypes, subgenotypes, serotypes or genetic/antigenic lineages in an individual or population of individuals.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 21, 2022
    Applicant: ConserV Bioscience
    Inventors: Olga PLEGUEZUELOS MATEO, Kimbell DUNCAN
  • PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE
    Publication number: 20200061185
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 27, 2020
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS CORONAVIRUS AND APPLICATION THEREOF
    Publication number: 20100304363
    Abstract: Disclosed herein are peptide compounds and the application thereof to the detection and inhibition of SARS coronavirus. Composed of dipeptides, the compounds for detecting and inhibiting SARS coronavirus can be readily synthesized and produced at low cost. In addition, they can be stored safely for a long period of time. The dipeptide compounds are useful as inhibitors of SARS coronavirus as well as acting as excellent capturing materials of SARS coronavirus.
    Type: Application
    Filed: May 26, 2010
    Publication date: December 2, 2010
    Applicant: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventors: Soo-Hyung LEE, Hyo-Bong Hong, Tao-Wan Kim, Myung-Ae Chung, Sung-Woo Sohn, Seoung-Min Yoo
  • Method of Treating Coronavirus
    Publication number: 20200179367
    Abstract: In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.
    Type: Application
    Filed: February 17, 2020
    Publication date: June 11, 2020
    Inventor: Jonnie R. Williams
  • DEVICES FOR DETECTING ANTIBODIES TO CORONAVIRUS ANTIGENS AND METHODS FOR USING THEM
    Publication number: 20230324402
    Abstract: In alternative embodiments, provided are multiplexed systems, compositions, including products of manufacture such as arrays, microarrays and biochips, and kits, and methods, for detecting presence of a coronavirus in a sample, or to detect a coronavirus, e.g., COVID-19, infection. In alternative embodiments, provided are methods for detecting the presence of a coronavirus infection in an individual. In alternative embodiments, provided are vaccines and methods for using them to prevent, mitigate or lessen to effects of, or treat a coronavirus infection in an individual.
    Type: Application
    Filed: March 23, 2021
    Publication date: October 12, 2023
    Inventors: Phillip L. FELGNER, Saahir KHAN, Algimantas JASINSKAS, Rie NAKAJIMA, Rafael RAMIRO DE ASSIS, Per Niklas HEDDE
  • MEDICAMENT AND FOOD FOR PREVENTING OR TREATING NOVEL CORONAVIRUS PNEUMONIA COVID-19 AND USE THEREOF
    Publication number: 20220305092
    Abstract: The use of lysozyme or combinations comprising the lysozyme in preparing a medicament for preventing or treating the novel coronavirus pneumonia COVID-19 and in preparing a food for assisting in preventing or treating the novel coronavirus pneumonia COVID-19 is disclosed. The lysozyme or the combination of the lysozyme, as provided by the present invention, can effectively inhibit cell damage caused by the novel coronavirus, inhibit the inflammatory factors expression induced by the novel coronavirus, ameliorate airway obstruction and decreased expiratory volume caused by lung lesions, and ameliorate intestinal barrier dysfunction. The lysozyme or the combination of the lysozyme has good effects on patients with high viral load, respiratory distress, impaired intestinal function, etc., and can reduce the novel coronavirus infection rate and the incidence rate of severe novel coronavirus pneumonia.
    Type: Application
    Filed: May 9, 2020
    Publication date: September 29, 2022
    Applicants: GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD, GUANGZHOU XIN-CHUANGYI BIOPHARMACEUTICAL CO., LTD, GUANGZHOU WELMAN NEW DRUG R&D CO., LTD., XIANGBEI WELMAN PHARMACEUTICAL CO., LTD, NANJING KANGFUSHUN PHARMACEUTICAL CO., LTD
    Inventors: Mingjie SUN, Tianyu SUN, Changqing LI
  • METHODS FOR SCREENING NOVEL CORONAVIRUS ANTIVIRALS AND METHODS OF USING ANTIVIRALS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
    Publication number: 20230293521
    Abstract: Disclosed are methods for screening for therapeutic agents that can inhibit a coronavirus infection and methods of using agents identified by said assays to treat a coronavirus infection.
    Type: Application
    Filed: July 14, 2021
    Publication date: September 21, 2023
    Inventors: Christopher Francis Basler, Jesus Silvas, Alexander Jureka
  • COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST CORONAVIRUS
    Publication number: 20230263882
    Abstract: Disclosed herein are CpG-amphiphiles and corona virus antigens (e.g., a coronavirus spike protein, a peptide thereof, or a nucleic acid sequence encoding the same) for use in inducing an immune response in a subject, and methods of administering CpG-amphiphiles and coronavirus antigens (e.g., a coronavirus spike protein, a peptide thereof, a coronavirus nucleocapsid protein, a peptide thereof, or a nucleic acid sequence encoding the same) to induce an immune response in a subject.
    Type: Application
    Filed: June 25, 2021
    Publication date: August 24, 2023
    Inventors: Martin P. STEINBUCK, Lochana M. SEENAPPA, Peter C. DEMUTH, Christopher M. HAQQ, Lisa MCNEIL
  • ANTI-NOVEL CORONAVIRUS MONOCLONAL ANTIBODY AND APPLICATION THEREOF
    Publication number: 20230174628
    Abstract: The present invention relates to the fields of immunology and molecular virology, and in particular, to the field of diagnosis, prevention and treatment of a novel coronavirus. Specifically, the present invention relates to an anti-novel coronavirus monoclonal antibody and a composition (for example, a diagnostic agent and a therapeutic agent) containing same. In addition, the present invention also relates to use of the antibody. The antibody of the present invention can be used for diagnosing, preventing and/or treating novel coronavirus infections and/or diseases (for example, novel coronavirus pneumonia) caused by the infections.
    Type: Application
    Filed: April 27, 2021
    Publication date: June 8, 2023
    Inventors: Xiaoliang Sunney XIE, Yunlong CAO, Wenjie SUN, Xu ZHANG
  • CORONAVIRUS VACCINE
    Publication number: 20230270841
    Abstract: The invention relates to vaccines, and in particular, to vaccines for preventing, treating or ameliorating coronavirus infections, such as severe acute respiratory syndrome coronavirus (SARS), SARS-CoV-2 and Middle East respiratory syndrome-related coronavirus (MERS). The invention is especially concerned with self-amplifying RNA replicons and genetic constructs or vectors encoding such RNA replicons, and their use in vaccine delivery for preventing infections of coronavirus. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.
    Type: Application
    Filed: March 26, 2021
    Publication date: August 31, 2023
    Applicant: Imperial College Innovations Limited
    Inventors: Robin Shattock, Paul McKay, Anna Blakney
  • Prefusion coronavirus spike proteins and their use
    Patent number: 10960070
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: March 30, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Prefusion coronavirus spike proteins and their use
    Patent number: 11964010
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: April 23, 2024
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason Mclellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • METHODS OF PREVENTING OR TREATING CORONAVIRUS INFECTION AND REDUCING CORONAVIRUS INFECTION RATE IN VITRO WITH ANTIVIRAL COMPOSITION COMPRISING POLY(3,4-ETHYLENEDIOXYTHIOPHENE):POLY(STYRENE SULFONATE)
    Publication number: 20230321138
    Abstract: The present invention provides methods of preventing or treating coronavirus infection and reducing coronavirus infection rate in vitro with antiviral composition comprising poly(3,4-ethylenedioxythiophene):poly(styrene sulfonate) (PEDOT:PSS), wherein the PEDOT:PSS is selected from PEDOT:PSS aqueous solutions in various formulas. Specifically, the molar ratio of PEDOT to PSS in the PEDOT:PSS aqueous solution in the antiviral composition may be 1:1.5 to 1:6 and the resistivity of the PEDOT:PSS aqueous solution in the antiviral composition may be 100 ?/sq to 5×107 ?/sq. The antiviral composition is used to inhibit the binding between the spike protein of the coronavirus and the host cells with angiotensin-converting enzyme 2 (ACE2) on surface. The coronavirus may be SARS-CoV-2.
    Type: Application
    Filed: June 14, 2022
    Publication date: October 12, 2023
    Inventor: Ming-Han TSAI
  • Almitrine for treating the hypoxemia of a coronavirus infection
    Publication number: 20230142073
    Abstract: Hypoxemia is an abnormally low O2 concentration in the blood. It can be lethal. When vital organs don't get enough O2 to operate properly. A coronavirus infection can cause hypoxemia. Wherein this is probably the most common cause of coronavirus associated death. COVID-19 has killed millions of people to date. A method comprising the administration of a therapeutically effective amount of almitrine dimesylate to a subject with a coronavirus infection. To treat/ameliorate/reduce/prevent any coronavirus associated hypoxemia in the subject. Therein increasing the subject's chance of survival.
    Type: Application
    Filed: March 15, 2021
    Publication date: May 11, 2023
    Inventor: Michael David Forrest
  • Method of treating coronavirus
    Patent number: 10918633
    Abstract: In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: February 16, 2021
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Fatty Acid Complexes Of Coronavirus Spike Protein And Their Use
    Publication number: 20230227506
    Abstract: Complexes of coronavirus spike proteins, as well as fragments or mutants thereof wherein the fragment or mutant thereof at least contains a receptor binding domain of said coronavirus spike protein, with linoleic acid, or a derivative or a salt or a mimetic thereof. Methods for producing the complexes of the invention by incubating coronavirus spike proteins with linoleic acid or a derivative or a salt or a mimetic thereof. . In vitro methods for identifying molecules which have therapeutic potential for diseases caused by coronaviruses by contacting the molecule with a coronavirus spike protein and linoleic acid or a derivative or salt or mimetic thereof. A method of treatment of coronavirus infection by administration of linoleic acid, or a derivative, a salt or a mimetic thereof to a subject in need thereof, by administration of an aerosol formulation or dry powder formulation to the respiratory tract, preferably by nasal administration.
    Type: Application
    Filed: June 18, 2021
    Publication date: July 20, 2023
    Inventors: Daniel Joseph Fitzgerald, Imre Berger, Christiane Berger-Schaffitzel, Christine Toelzer, Kapil Gupta
Narrow Results

Filter by US Classification